Dogwood Therapeutics (NASDAQ:DWTX) Issues Earnings Results

Dogwood Therapeutics (NASDAQ:DWTX) posted its quarterly earnings results on Monday. The company reported ($6.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($4.80), Zacks reports.

Dogwood Therapeutics Stock Down 11.2 %

Shares of Dogwood Therapeutics stock traded down $0.63 during trading hours on Monday, reaching $5.01. 158,199 shares of the stock traded hands, compared to its average volume of 1,909,165. Dogwood Therapeutics has a one year low of $1.62 and a one year high of $29.28. The company has a market capitalization of $6.67 million, a price-to-earnings ratio of -0.76 and a beta of 2.07. The business’s 50 day moving average is $7.67.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.